Brambilla Francesca, Amianto Federico, Dalle Grave Riccardo, Fassino Secondo
The University Department of Psychiatry, San Paolo Hospital, Milano, Italy.
University Department of Psychiatry, Torino, Italy.
BMC Psychiatry. 2014 Dec 24;14:376. doi: 10.1186/s12888-014-0376-7.
Treatments of eating disorders result too often in partial psychological and physical remission, chronicization, dropout, relapse and death, with no fully known explanations for this failure. In order to clarify this problem, we conducted three studies to identify the biochemical background of cognitive-behavioural psychotherapy (CBT), individual psychology brief psychotherapy (IBPP), and psychotherapy-pharmacotherapy with CBT + olanzapine in anorexics (AN) and bulimics (BN) by measuring the levels of plasma homovanillic acid (HVA) for dopamine secretion, plasma 3-methoxy-4-hydroxy-phenylglycol (MHPG) for noradrenalin secretion, and platelet [3H]-Paroxetin-binding Bmax and Kd for serotonin transporter function. The data were then compared with psychopathological and physical alterations.
Study 1 investigated the effects of 4 months of CBT on plasma HVA, MHPG and [3H]-Par-binding in 14 AN-restricted, 14 AN-bingeing/purging, and 22 BN inpatients. Study 2 investigated the effects of 4 months of IBPP on plasma HVA in 15 AN and 17 BN outpatients. Study 3 investigated the effect of 3 months of CBT + olanzapine (5 mg/day) in 30 AN outpatients. The data were analyzed using one-way ANOVA for repeated measures for the changes between basal and post-treatment biological and psychological parameters, two-way ANOVA for repeated measures for the differences in the psychobiological data in the 3 groups, Spearman's test for the correlations between basal and final changes in the psychological and biological scores.
Study 1 revealed significant amelioration of the psychopathology in the AN and BN patients, no effects on HVA, MHPG or Paroxetin binding Kd, and a significant increase in Par-binding Bmax only in the BN patients. Study 2 revealed a significant effect of IBPP on psychopathology in the AN and BN patients, and a significant increase in HVA only in the BN patients. Study 3 revealed a significant positive effect of CBT + olanzapine therapy on the psychopathology and increased HVA values. No correlations were observed in the 3 groups between biological and psychological effects of the three treatments.
Our data advance suggestions on the mechanism of action of the three therapies; however, the lack of correlations between biochemical and psychological effects casts doubt on their significance. Clinical Trials.gov. Identifier NCT01990755 .
饮食失调的治疗常常导致部分心理和身体症状缓解、病情慢性化、患者退出治疗、复发甚至死亡,而对于这种治疗失败的原因尚无完全明确的解释。为了阐明这一问题,我们开展了三项研究,通过测量血浆高香草酸(HVA)水平以评估多巴胺分泌、血浆3-甲氧基-4-羟基苯乙二醇(MHPG)水平以评估去甲肾上腺素分泌,以及血小板[3H]-帕罗西汀结合的最大结合容量(Bmax)和平衡解离常数(Kd)以评估5-羟色胺转运体功能,来确定认知行为疗法(CBT)、个体心理短程疗法(IBPP)以及CBT联合奥氮平的心理治疗-药物治疗对神经性厌食症(AN)和神经性贪食症(BN)患者的生化背景。然后将这些数据与心理病理学和身体改变进行比较。
研究1调查了4个月的CBT对14例限制型AN、14例暴食/清除型AN和22例BN住院患者血浆HVA、MHPG和[3H]-帕罗西汀结合的影响。研究2调查了4个月的IBPP对15例AN门诊患者和17例BN门诊患者血浆HVA的影响。研究3调查了3个月的CBT联合奥氮平(5毫克/天)对30例AN门诊患者的影响。使用单向方差分析重复测量法分析基础和治疗后生物及心理参数之间的变化,使用双向方差分析重复测量法分析3组心理生物学数据的差异,使用Spearman检验分析心理和生物学评分基础和最终变化之间的相关性。
研究1显示AN和BN患者的心理病理学有显著改善,对HVA、MHPG或帕罗西汀结合Kd无影响,仅BN患者的帕罗西汀结合Bmax显著增加。研究2显示IBPP对AN和BN患者的心理病理学有显著影响,仅BN患者的HVA显著增加。研究3显示CBT联合奥氮平治疗对心理病理学有显著积极影响且HVA值增加。在3组中未观察到三种治疗的生物学和心理效应之间存在相关性。
我们的数据为三种疗法的作用机制提出了建议;然而,生化和心理效应之间缺乏相关性令人对其意义产生怀疑。ClinicalTrials.gov标识符:NCT01990755。